An Evaluation Of Oregon s Evidence-Based Practitioner- Managed Prescription Drug Plan
|
|
- Phillip Waters
- 5 years ago
- Views:
Transcription
1 Oregon s Drug Plan An Evaluation Of Oregon s Evidence-Based Practitioner- Managed Prescription Drug Plan Oregon s effort to manage drug usage helped curb spending, but health outcomes for patients have not been ascertained. by Daniel M. Hartung, Kathy L. Ketchum, and Dean G. Haxby ABSTRACT: This paper describes Oregon s implementation of its publicly developed, evidence-based, Practitioner-Managed Prescription Drug Plan (PMPDP). Oregon s PMPDP was initially self-enforced with a dispense as written (DAW) exception process, followed by an educational prior authorization (soft PA) method, and finally no active enforcement. Marketshare trends indicate that the educational prior authorization process was most effective at increasing the use of preferred agents. Pharmacy costs decreased 9.1 percent and 17.7 percent after implementation of the DAW and soft PA policies, respectively. Data from nonenforced PMPDP classes showed no change; this suggests the need for effective methods to encourage PMPDP compliance. [Health Affairs 25, no. 5 (2006): ; /hlthaff ] Sharp declines in revenues combined with rapidly rising health care spending have forced many states to adopt far-reaching measures to sustain their Medicaid programs. 1 Prescription drugs are a key driver of health care costs for state Medicaid programs and a frequent target for cost-controlling programs. In response to these pressures, in August 2001 Oregon enacted Senate Bill (SB) 819, which mandated development of the Practitioner-Managed Prescription Drug Plan (PMPDP) for the fee-for-service (FFS) Medicaid program. 2 The intent of SB 819 was to provide Oregonians the most effective drugs in the most costeffective manner by developing a process that systematically identified the most effective drugs within a class. Preferred drug lists (PDLs) are common among state Medicaid programs; however, Oregon s approach to both establishing and implementing its list was unique. Here we describe the methods used to develop and im- Daniel Hartung is assistant director of research and program evaluation in the Drug Use Research and Management Program, College of Pharmacy, Oregon State University, in Portland. Kathy Ketchum is coordinator of Medicaid-related programs. Dean Haxby (haxbyd@ohsu.edu) is an associate professor of pharmacy and director of the Drug Use Research and Management Program. HEALTH AFFAIRS ~ Volume 25, Number DOI /hlthaff Project HOPE The People-to-People Health Foundation, Inc.
2 DataWatch plement the PMPDP, examine prescription drug use after it took effect, and estimate cost savings attributable to this policy. PMPDP list development process. Establishment of the Oregon PMPDP was predicated on a several-step process outlined in the original legislation. First, SB 819 asserted that Oregon Medicaid enrollees should have access to the most effective prescription drugs for their clinical conditions. Effectiveness was to be determined by health practitioners, who are informed by the latest peer-reviewed research. Finally, cost was to be considered only after the relative clinical effectiveness was established and then managed through market competition. Comparative effectiveness was evaluated using a systematic process; employing established methods of evidence-based medicine; and open to input from the public, stakeholders, and the pharmaceutical industry. 3 The use of an evidence-based approach for policy development is not novel;however,thescopeandtransparency of Oregon s process makes it unique among both public and private health care payers. 4 Theevidence-basedreviewprocesshasbeenreviewedindetailelsewhere. 5 The first step in the process developed key effectiveness and safety questions. To build community consensus about what effectiveness and safety outcomes were important, volunteer committees of local health care practitioners and members of the public were convened to develop the questions. Clinicians were restricted from participating in the subcommittees if they had major financial conflicts of interest. Key questions varied by drug class but generally focused on the comparative effectiveness, drug safety, and differential effects among subpopulations (for example, by sex, age, or race). Draft questions were posted to a Web site to allow publicreview,comment,andtestimony. 6 Once finalized, key questions were submitted to an Evidence-based Practice Center (EPC) to conduct the literature search and systematic evidence review. For each drug class, the EPC conducted a systematic literature search identifying the key peer-reviewed studies relevant to each specific key question. Comprehensive reports generated by the EPC were used by the committees, in conjunction with public comment and testimony, to determine which drugs were most effective and safe within the class as dictated by the key questions. Committee reports were submitted to the Oregon Department of Human Services for price determination. If the practitioner committee determined that the evidence did not support clinically meaningful differences between drugs within a class, then all comparatively effective drugs, competitively priced to the least expensive (benchmark) agent, were selected as preferred drugs on the PMPDP. A standing update committee was also established to meet regularly and evaluate new evidence or new drugs in the reviewed classes based on a preliminary EPC-generatedupdatereport.Iftheupdatecommitteebelievedthatnewconclusions would be drawn, the drug-specific practitioner committees were reconvened with the standing update committee for a review of the new evidence September/October 2006
3 Oregon s Drug Plan Implementation. The first four reviewed drug classes were implemented in August (proton pump inhibitors, or PPIs, and long-acting opioids) and September (nonsteroidal anti-inflammatory drugs, or NSAIDs, and statins) Initially, the PMPDP was practitioner-enforced, and prescribers were given a simple way to prescribe off the list. If a prescriber determined that a patient required a nonpreferred PMPDP medication, the prescriber had the option of writing dispense as written (DAW exception) on the prescription to notify the pharmacist to override the policy. Dispensing pharmacists played a key education role during this period, because they were responsible for notifying prescribers of the need for an override. Because the initial changes in use did not meet anticipated budget targets, the state implementedanadministrativeruleinmay2003requiringprescriberstocontactthe state s pharmacy benefit administrator to hear an educational message about the comparative evidence. The soft prior authorization (PA) did not require the prescriber to use a preferred agent or submit justification for the nonpreferred selection. Only the first four classes were subject to these enforcement policies (DAW exemption, soft PA). In October 2003, legislation was passed that prohibited any active enforcement of the PMPDP, thereby revoking the soft PA administrative rule. 7 All classes added subsequent to October 2003 have not been subject to any enforcement. Under this voluntary process, the PMPDP was expanded in May 2003 to include estrogens and in November 2003 to include overactive bladder drugs, oral hypoglycemics, skeletal muscle relaxants, and triptans. Evaluation Methods Prescription drug claims from January 2001 through June 2004 were used to evaluate the impact of the various enforcement methods on the first four drug classes (PPIs, NSAIDs, long-acting opioids, and statins). There was a thirty-fourday supply limit on dispensed drugs during the evaluation period. Usage over the study period was divided into four distinct time periods: pre-policy period (1 January 2001 through 31 July 2002 or 31 August 2002 for PPIs and long-acting opioids, or NSAIDs and statins, respectively), DAW exception period (1 August 2002 or 1 September 2002, depending on class, through 30 April 2003), soft PA period (1 May 2003 through 30 September 2003), and voluntary period (1 October 2003 through 30 June 2004). The proportion of prescriptions dispensed as preferred PMPDP agents (PMPDP market share) was quantified and averaged over each period. Changes in market share were quantified as the relative change of one period overtheprevious.thelistwasdynamicbecausethepreferredpmpdpagents changed depending on pricing variation or the emergence of new evidence (such as new outcome evidence for atorvastatin within statin class). To better account for these list changes, the proportion of prescriptions dispensed as the PMPDP benchmark agent, which did not change during the evaluation period, was evaluated similarly. Market-share trend analyses were also conducted on the drug classes that were not subject to direct enforcement (for example, triptans, oral HEALTH AFFAIRS ~ Volume 25, Number
4 DataWatch hypoglycemics, overactive-bladder drugs, and skeletal-muscle relaxants) eight months before and after they were added to the PMPDP. Estrogen use was not evaluated because of the concomitant changes in prescribing occurring as a result oftherecentnegativefindingsabouthormonereplacementtherapy. 8 A cost analysis was performed for the NSAIDs, long-acting opioids, PPIs, and statins. Cost trends were estimated using the ingredient cost per enrolled member per month and adjusted for federal and supplemental rebates. A segmented ordinary least squares linear regression analysis on class-specific and total cost per member per month was performed using the time segments described above. 9 Coefficientsreflectingaone-timeimmediatechangearepresentedasthepercentage difference of the expected trend if the policy had not been implemented. Changes in trend are reported as the absolute increase or decrease in slope. Statistical analyses were performed with SAS version 9.1. Program savings were estimated taking the difference between a linear projection of total cost per member per month and the observed cost per member per month adjusted for the cost of administering the soft PA during that time. In January 2003, in the midst of a major budget shortfall, the OHP reorganized its Medicaid program into two distinct benefit packages that differed in benefit structure: Oregon Health Plan (OHP) Plus and OHP Standard. 10 Another component of the restructuring involved instituting various cost-sharing mechanisms such as copayments for drugs and services, which varied dramatically between the OHP Plus and OHP Standard populations. Most notably, OHP Standard enrollees were required to pay copays between $3 for generics and $15 for brandname prescription drugs. Clients enrolled in OHP Plus were asked, but not required, to pay copays of between $2 for generics and $3 per brand-name prescription. To minimize the confounding effects of this policy, we excluded all OHP Standard benefit recipients from our analysis. Study Results Market share. The average monthly enrollment in the OHP FFS program during the months of our study was 129,021; it remained relatively stable throughout. The average fluctuation from month to month was 1.8 percent. During the evaluation period, the PMPDP and how it was enforced changed several times, particularly for the first four classes reviewed (Exhibit 1). In addition to the two policy changes, two major PMPDP preferred list changes occurred during the evaluation period. In April 2004, Zocor, Lescol, Lescol XL, Lipitor, and Altocor were added to the preferred statin list. Duragesic was removed from the long-acting opioid list in November To adjust for these drug changes, we performed another analysis of percentage of prescriptions dispensed as the PMPDP benchmark (lowest-cost agent) (Exhibit 2). The benchmark agents for the initial four classes remained constant during the evaluation period. The average monthly market-share figures for each 1426 September/October 2006
5 Oregon s Drug Plan EXHIBIT 1 Monthly Market Share For Drugs In The Oregon Practitioner-Managed Prescription Drug Plan (PMPDP), By Drug Class, January 2001 June 2004 Percent PMPDP preferred 100 All statins added except Crestor PPIs Long-acting opioids NSAIDs Duragesic removed 0 Statins DAW policy Soft PA Voluntary 1/01 7/01 1/02 7/02 1/03 7/03 SOURCE: Oregon Health Plan fee-for-service pharmacy claims data, various years. NOTES: Proportion of prescriptions in four initially implemented drug classes dispensed as PMPDP preferred drugs. PPI is proton pump inhibitor. NSAID is nonsteroidal anti-inflammatory drug. DAW is dispense as written. PA is prior authorization. Because there are two possible starting dates for the DAW period (August or September 2002), two gray lines are shown. 1/04 policy period for all preferred and benchmark drugs are shown in Exhibit 3. The statin class was the most profoundly affected by the PMPDP implementation. After the DAW exception was activated, market share of preferred agents increased 28 percent overall. Market share for preferred statins doubled, and preferred NSAID use increased the least. After the soft PA was employed, the use of preferred products in aggregate increased 43 percent, from 58 percent to 82 percent. Again, the use of preferred statins demonstrated the greatest increase, followed by NSAIDs. Preferred PPI market share increased the least. When the soft EXHIBIT 2 Benchmark Market Share For Drugs In The Oregon Practitioner-Managed Prescription Drug Plan (PMPDP), By Drug Class, January 2001 June 2004 Percent PMPDP preferred 80 DAW policy Soft PA Voluntary 60 PPIs /01 7/01 1/02 7/02 1/03 7/03 Statins NSAIDs Long-acting opioids 1/04 SOURCE: Oregon Health Plan fee-for-service pharmacy claims data, various years. NOTES: Proportion of prescriptions in four initially implemented drug classes dispensed as benchmark drugs. PPI is proton pump inhibitor. NSAID is nonsteroidal anti-inflammatory drug. DAW is dispense as written. PA is prior authorization. Because there are two possible starting dates for the DAW period (August or September 2002), two gray lines are shown. HEALTH AFFAIRS ~ Volume 25, Number
6 DataWatch EXHIBIT 3 Summary Of The Oregon Practitioner-Managed Prescription Drug Plan (PMPDP) Market Share, January 2001 July 2004 DAW exception (%) Soft PA (%) Voluntary (%) Drug class: PMPDP preferred Baseline Market share Percent change Market share Percent change Market share Percent change PPI Long-acting opioid NSAID Statin Aggregate Benchmark PPI (Protonix) Long-acting opioid (LA- Morphine) NSAIDs (Naproxen) Statins (Lovastatin) SOURCE: Authors analysis based on Oregon Health Plan fee-for-service pharmacy claims. NOTES: Proportion of prescriptions dispensed as a PMPDP preferred drug and benchmark drug for initially implemented drug classes during each of the four policy segments (see text for time periods involved). For each policy change, the average monthly proportion and the percentage change compared with the previous period are reported. Baseline period for statin benchmark only includes time when commercially available (January August 2002). PPI is proton pump inhibitor. NSAID is nonsteroidal anti-inflammatory drug. PA policy was retracted, overall PMPDP preferred market share decreased overall 17 percent. NSAIDs showed the largest decrease. The 37 percent reduction in preferred long-acting opioid use was attributable to the removal of Duragesic as a preferred agent. When we restricted the market-share analysis to just the benchmark drug, generic long-acting morphine use dropped only 4 percent. Generally speaking, the benchmark drug market-share trends followed a pattern similar to that of the overall preferred PMPDP market share. Overactive-bladder drugs, skeletal-muscle relaxants, oral hypoglycemics, and triptanswereaddedtothepmpdpinnovember2003.asidefrombeingpostedon the Medicaid Web site, no formal policies were implemented to encourage their use. No discernible changes in the use of preferred drugs were observed after these classes were added to the PMPDP (Exhibit 4). Cost analysis. Exhibit 5 shows the results of the segmented regression models. The aggregate model demonstrates that implementation of the DAW exception was associated with a 9.1 percent immediate per member per month cost decrease, as well a significant reduction in overall trend. The soft PA period was associated with a 17.7 percent immediate decrease, along with a significant increase in slope of $0.28. Within the specific classes, our model showed that the DAW period was associated with statistically significant abrupt declines of percent. Significant immediate decreases of percent were detected after establishment of the soft PA. Elimination of the soft PA was not accompanied by any statistically sig September/October 2006
7 Oregon s Drug Plan EXHIBIT 4 Market Share Of Nonenforced Practitioner-Managed Prescription Drug Plan (PMPDP) Drug Classes, Before And After Listing On PMPDP, 1 November 2003 Market share Drug class Before (%) After (%) Percent change Skeletal muscle relaxants Urinary incontinence Oral hypoglycemics Triptans SOURCE: Authors analysis based on Oregon Health Plan fee-for-service pharmacy claims. NOTES: Proportion of prescriptions dispensed as a PMPDP preferred agent for nonenforced classes eight months before and after listing on PMPDP. The average monthly proportion and the percentage change (in percentage points) compared with the previous period are reported. EXHIBIT 5 Regression Results: Segmented Linear Regression Models Of Individual Class And Aggregate Costs Per Member Per Month, Oregon Practitioner-Managed Prescription Drug Plan (PMPDP), January 2001 June 2004 Drug class Baseline Aggregate PPI Long-acting opioid NSAID Statin Intercept Baseline trend $5.30** ($5.09, $5.51) $0.18** ($0.16, $0.19) $0.84** ($0.73, $0.94) $0.05** ($0.04, $0.06) $2.22** ($2.07, $2.36) $0.06** ($0.05, $0.07) $1.35** ($1.28, $1.42) $0.02** ($0.01, $0.02) $0.93** ($0.88, $0.98) $0.05** ($0.04, $0.05) DAW exception policy initiated Immediate change Trend change 9.1%** ( 13.8%, 4.3%) $0.18** ( $0.08, $0.02) 6.7% ( 17.2%, 3.9%) $0.05** ( $0.05, $0.03) 9.9%** ( 17.4%, 14.2%) $0.01 ( $0.06, $0.01) 14.6%** ( 22.5%, 6.6%) $0.04** ( $0.07, $0.03) 8.8%** ( 13.7%, 3.9%) $0.05** ( $0.08, $0.02) Soft PA policy initiated Immediate change Trend change 17.7%** ( 25.4%, 10.0%) $0.28** ($0.11, $0.44) 10.1% ( 26.5%, 6.2%) $0.06 ( $0.01, $0.14) 17.5%** ( 27.9%, 7.2%) $0.08 ( $0.02, $0.19) 42.0%** ( 56.5%, 27.4%) $0.01 ( $0.05, $0.06) 11.0%** ( 19.3%, 2.8%) $0.07 ($0.03, $0.11) Voluntary policy initiated Immediate change Trend change 5.5% ( 1.1%, 12.1%) $0.10 ( $0.26, $0.06) 2.8% ( 16.1%, 10.4%) $0.02 ( $0.10, $0.05) 4.4% ( 4.6%, 13.3%) $0.10 ( $0.20, $0.00) 46.6%** (22.5%, 70.7%) $0.06** ($0.01, $0.11) 9.0%** (2.6%, 15.5%) $0.02 ( $0.06, $0.02) SOURCE: Authors analysis based on Oregon Health Plan fee-for-service pharmacy claims. NOTES: Immediate changes are expressed as percentage change from expected. Trend changes are expressed as absolute change in change in slope from previous period (see text for time periods involved). 95 percent confidence intervals are in parentheses. PPI is proton pump inhibitor. NSAID is nonsteroidal anti-inflammatory drug. DAW is dispense as written. PA is prior authorization. **p <.05 HEALTH AFFAIRS ~ Volume 25, Number
8 DataWatch nificant change in aggregate cost per member per month. However, immediate 46.6 percent and 9.0 percent increases in costs were observed in the NSAID and statin class, respectively, after the soft PA was repealed. Exhibit 6 shows observed and predicted spending for the first four PMPDP classes before and after the two policies were implemented. Overall, we estimate that the DAW exception was responsible for an average monthly reduction of $1.41 per member per month (95 percent confidence interval: $0.80, $2.78), or $191,932 in total (95 percent CI: $108,456, $275,409) in monthly savings. The PA policy was projected to reduce spending by $3.58 per member per month (95 percent CI: $2.78, $4.37) or a total of $444,660 (95 percent CI: $363,205, $570,870) per month. During the entire period, the DAW policy and soft PA saved an estimated $1,727,392 (95 percent CI: $976,102, $2,478,682) and $2,223,300 (95 percent CI: $1,816,027, $2,854,353) in pharmacy costs, respectively. Discussion This analysis, which focused on the implementation of the PMPDP, demonstrated that the use of both a DAW exception and a soft PA method were effective at reducing spending and shifting market share within the four initially implemented drug classes in the PMPDP. The DAW exception policy shifted market share toward preferred agents by 28 percent. The market share of preferred agents rose another 43 percent after the soft PA took effect. Revocation of these policies in October 2003 for the initial classes has contributed to a reversal of previously established market-share gains. NSAIDs and long-acting opioids experienced the largest reversal of preferred drug market share after the soft PA was eliminated. Negligible market-share changes occurred in classes that were not subject to any EXHIBIT 6 Cost Prediction Model: Aggregate Per Member Per Month Costs Predicted And Observed Over Time For Four Initial Oregon Practitioner-Managed Prescription Drug Plan (PMPDP) Drug Classes, January 2001 June 2004 Dollars Observed Predicted 95% CI DAW policy Soft PA Voluntary 1/01 7/01 1/02 7/02 1/03 7/03 1/04 SOURCE: Authors analysis based on Oregon Health Plan fee-for-service pharmacy claims data, various years. NOTES: Prediction model is of the form y = ß0 + ß 1 x 1, for model p <.0001, adjusted R 2 = CI is confidence interval. DAW is dispense as written. PA is prior authorization September/October 2006
9 Oregon s Drug Plan active enforcement policy. Cost savings were estimated to occur in the initial PMPDP drug classes under both enforcement strategies. Total per member per month costs were reduced significantly, as both an immediate reduction and a decrease in the month-to-month trend, for both the DAW policy and soft PA. These decreases translate into approximately $4 million in pharmacy program savings over the life of both policies. It is estimated that almost 70 percent of state Medicaid programs use PDLs to assist in managing drug spending. 11 However, similar to other drug management strategies, little is known about these policies impact on economic or health outcomes. 12 The general lack of information about PDLs is further compounded by the considerable heterogeneity with respect to how PDLs are synthesized and enforced in various state Medicaid programs. Although nearly all states use clinical evidence to help decide which drugs will be included on their lists, Oregon is unique in the explicit process it uses to evaluate and compare this evidence. Both the DAW exception and educational soft PA enforcement methods were also unique among Medicaid programs. Study limitations. Several important limitations of our study should be considered. One potential confounding factor was the implementation of a patient copay policy in January of Prescription drug cost-sharing policies have been demonstrated to reduce use and potentially shift market share. Although we attempted to control for this by excluding clients who faced the highest copayment schedule, it is impossible to completely eliminate its effect. Trends described in Exhibits 1, 2, and 6 do not appear to show any major effect after the copay policy was implementedinjanuary2003.thisanalysisdidnotevaluateimpactonuseofother health services. Several of the shifts in PMPDP use were large enough that a closer evaluation of unintended health outcomes will be critical in assessing this program s overall impact. In addition, the added administrative burden for health care providers caring for OHP enrollees was not formally considered in this analysis. Concerns about the process. Many have expressed concerns and skepticism about the process in which Oregon has translated clinical evidence into policy. Challenges to the process include developing questions that adequately capture important outcomes, identifying and evaluating unpublished data, the insufficient quantity of high-quality research, lack of direct comparative studies between drugs, how to appropriately integrate evidence from observational research, and how to fairly deal with potential conflicts of interest at several levels. Also, the reviews focused only on comparing agents within a class and did not compare agents from different classes that could be used for the same condition. Finally, while the EPCgenerated reviews made no claims of therapeutic equivalence when evidence was lacking to suggest a difference between drugs within classes, the state made its preferred drug selections based on this assumption. Some have argued that agents should not be selected for the PDL when evidence is lacking to establish whether or not a true difference exists. 13 HEALTH AFFAIRS ~ Volume 25, Number
10 DataWatch Oregon has adopted a unique system for translating the principles of evidence-based medicine into policy decisions regarding the use of prescription drugs. However, translating this research into meaningful changes in practice has lagged somewhat because of lack of enforcement mechanisms aimed at encouraging preferred drug use. Our data suggest that for an evidence-based PDL to have an impact on drug use or costs, effective methods of promoting evidence-based choices need also be employed. Data from nonenforced classes suggest that having an evidence-based process to determine preferred agents alone is not sufficient for changing prescribing behavior. The state is now using educational techniques such as faxed prescription-change forms and provider detailing to disseminate research generated from the comparative reviews. This work was supported by the Oregon State University College of Pharmacy, which receives funding from the Oregon Office of Medical Assistance Programs. NOTES 1. J. Crowley, D. Ashner, and L. Elam, Medicaid Outpatient Prescription Drug Benefits: Findings from a National Survey, December 2003, (accessed 30 May 2006); M.M. Mello, D.M. Studdert, and T.A. Brennan, The Pharmaceutical Industry versus Medicaid Limits on State Initiatives to Control Prescription-Drug Costs, New England Journal of Medicine 350, no. 6 (2004): ; and J.K. Iglehart, The Dilemma of Medicaid, New England Journal of Medicine 348, no. 21 (2003): Oregon Legislative Assembly Senate Bill 819, 71st Oregon Legislative Assembly, 2001 Regular Session. 3. Drug Effectiveness Review Project, Quality Assessment Methods for Drug Class Reviews for the Drug Effectiveness Review Project, (accessed 13 February 2006). 4. A.M. Garber, Evidence-based Coverage Policy, Health Affairs 20, no. 5 (2001): C. Bernasek et al., Oregon s Medicaid PDL: Will an Evidence-based Formulary with Voluntary Compliance Set a Precedent for Medicaid? January 2004, (accessed 18 April 2006). 6. Oregon s Practitioner-Managed Drug Plan, Evidence-based Medicine Reports, DAS/OHPPR/ORRX/HRC/evidence_based_reports.shtml (accessed 18 April 2006). 7. Oregon Legislative Assembly House Bill 3624, 72d Oregon Legislative Assembly, 2003 Regular Session. 8. J.E. Rossouw et al., Risks and Benefits of Estrogen plus Progestin in Healthy Postmenopausal Women: Principal Results from the Women s Health Initiative Randomized Controlled Trial, Journal of the American MedicalAssociation 288, no. 3 (2002): ; and D. Grady et al., Cardiovascular Disease Outcomes during 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II), Journal of the American Medical Association 228, no. 1 (2002): A.K. Wagner et al., Segmented Regression Analysis of Interrupted Time Series Studies in Medication Use Research, Journal of Clinical Pharmacy and Therapeutics 27, no. 4 (2002): Details about the modeling process are described in an online appendix, available at 25/5/1423/DC C. Mann and S. Artiga, The Impact of Recent Changes in Health Care Coverage for Low-Income People: A First Look at the Research following Change in Oregon s Medicaid Program, Issue Paper, June 2004, (accessed 13 February 2006). 11. Crowley et al., Medicaid Outpatient Prescription Drug Benefits. 12. S.B. Soumerai, Benefits and Risks of Increasing Restrictions on Access to Costly Drugs in Medicaid, Health Affairs 23, no. 1 (2004) J.D. Kleinke, Evidence-based Medicine: Health Care s Next Holy War, Journal of Managed Care Pharmacy 11, no.4supp.(2005):s3 S6;andR.Padrezetal.,The Use of Oregon s Evidence-based Reviews for Medicaid Pharmacy Policies: Experiences in Four States, May 2005, (accessed 18 April 2006) September/October 2006
Managed Care Trends in Statin Usage GARY R. BAZALO, MS, MBA
PHARMACY UTILIZATION Managed Care Trends in Statin Usage GARY R. BAZALO, MS, MBA ABSTRACT Purpose HMG-CoA reductase inhibitors ( statins ) have become the drug class of choice for the treatment of hyperlipidemia.
More information2017 Drug Trends Series
2017 Drug Trends Series Part 1 Evaluating the traditional view Retail and mail-order prescriptions Published April 2018 1 2017 Drug Trends Series Traditional View First Script A year of important progress
More informationANN M. HAMER, PharmD, BCPP; DANIEL M. HARTUNG, PharmD; DEAN G. HAXBY, PharmD; KATHY L. KETCHUM, RPh, MPA:HA; and DAVID A.
RESEARCH Initial Results of the Use of Prescription Order Change Forms to Achieve Dose Form Optimization (Consolidation and Tablet Splitting) of SSRI Antidepressants in a State Medicaid Program ANN M.
More informationMedication trends shaping workers compensation. A 2018 update of the prevailing industry influences impacting pharmacy outcomes
Medication trends shaping workers compensation A 2018 update of the prevailing industry influences impacting pharmacy outcomes This page intentionally left blank Trends impacting workers compensation pharmacy
More informationMedicaid provides prescription drugs for certain
At a Glance Impact of Medicaid Preferred Drug List on Long-Acting Opioid Users Practical Implications p 210 Author Information p 215 Full text and PDF www.ajpblive.com Natalie R. Jacuzzi, MPH; K. John
More informationStrategies to Prevent Pharmaceutical Waste: Modifying Co-Pay Structures
Modifying Co-Pay Structures Extended producer responsibility (EPR) is a policy approach in which the producer s responsibility for their product extends to the post-consumer management of that product
More informationSummary of Related Documentation Pennsylvania House Bill 1846 of 2014
Summary of Related Documentation Pennsylvania House Bill 1846 of 2014 15 November 2018 Department of Labor & Industry BWC-Administrative Division 1171 S. Cameron St. Harrisburg PA 17104-2501 Essential
More informationMichigan Legislative and Regulatory Pharmacy Initiatives Update
Michigan Legislative and Regulatory Pharmacy Initiatives Update Michigan Association of Health Plans Summer Conference Carrie Germain, R.Ph. Health Alliance Plan Senior Director, Pharmacy, Quality and
More information2017 Legislative Policy Update
2017 Legislative Policy Update Aliyah N. Horton, CAE Executive Director Maryland Pharmacists Association Presentation Overview Maryland Pharmacists Association General highlights of the session Pharmacy-related
More informationMedicaid Cost Containment and Potential Effects on Diabetic Beneficiaries
Medicaid Cost Containment and Potential Effects on Diabetic Beneficiaries White Paper October 2003 2003 The Health Strategies Consultancy LLC and Duke University, The Fuqua School of Business For more
More informationThe STOP Measure. Safe and Transparent Opioid Prescribing to Promote Patient Safety and Reduced Risk of Opioid Misuse FEBRUARY 2018
The STOP Measure Safe and Transparent Opioid Prescribing to Promote Patient Safety and Reduced Risk of Opioid Misuse FEBRUARY 2018 AHIP s Safe, Transparent Opioid Prescribing (STOP) Initiative Methodology
More informationCurbing Prescription Drug Abuse in Medicaid
Curbing Prescription Drug Abuse in Medicaid Joint Legislative Health Care Oversight Committee October 12, 2010 Dr. Lisa Weeks, BSPharm, PharmD Pharmacy and Ancillary Services Division of Medical Assistance
More informationMaryland Department of Health and Mental Hygiene /Office of Systems, Operations and Pharmacy. Date Prescription will Start Denying at the
Maryland Medicaid Pharmacy Program & News ViewsNovember 2013 Maryland Department of Health and Mental Hygiene /Office of Systems, Operations and Pharmacy The Antipsychotic Peer Review Program is Expanding!
More informationThe Sustainability of Irish Pharmaceutical Expenditure. Valerie Walshe Ph.D. Economist
The Sustainability of Irish Pharmaceutical Expenditure Valerie Walshe Ph.D. Economist valerie.walshe@hse.ie February 2015 Content Overview of Irish Health Services Community Drug Prescribing Trends Driving
More informationMiami-Dade County Prepaid Dental Health Plan Demonstration: Less Value for State Dollars
Miami-Dade County Prepaid Dental Health Plan Demonstration: Less Value for State Dollars Analysis commissioned by The Collins Center for Public Policy / Community Voices Miami AUGUST 2006 Author: Burton
More informationPharmacy benefit guide
FlexRx SM 5-Tier Pharmacy benefit guide 1 Welcome to FlexRx The NHP FlexRx SM program is built for choice, savings, and convenience with benefits including: Low-cost drug tier for many common medications
More informationOHSU Digital Commons. Oregon Health & Science University. Natalie R. Jacuzzi. Scholar Archive. June 2007
Oregon Health & Science University OHSU Digital Commons Scholar Archive June 2007 The impact of the practitioner managed prescription drug plan on health service utilization for Oregon Health Plan fee-for-service
More informationWashington State Medicaid Prescription Drug Purchasing: Preferred Drug List
Washington tate Medicaid Prescription rug Purchasing: Preferred rug List NLPE Conference eptember 21, 2011 John Bowden Joint Legislative udit & eview Committee JLC Background he Joint Legislative udit
More informationPHARMACY Section 9. Overview. Preferred Drug List. Additions and Exceptions to the Preferred Drug List
Overview The management of outpatient prescription drugs is an integral part of the medical management program to improve the health and well-being of our members. Prescriber and member involvement is
More informationIdaho DUR Board Meeting Minutes
Idaho DUR Board Meeting Minutes Date: July 20, 2017 Time: 9am-12:30pm Location: Holiday Inn Boise Airport 2970 West Elder Street, Boise, Idaho, 83705 Moderator: David Agler, M.D. Committee Member Present:
More informationReport to the Social Services Appropriations Subcommittee
Report to the Social Services Appropriations Subcommittee Medicaid Coverage and Reimbursement for Outpatient Physical Therapy and Outpatient Occupational Therapy Prepared by the Division of Medicaid and
More informationDrugs are the fastest-growing component
Health Tracking MarketWatch Impact Of Medicaid Prior Authorization On Angiotensin-Receptor Blockers: Can Policy Promote Rational Prescribing? Most state programs are ineffective at controlling either use
More informationPatient-Centered Oncology Payment: Payment Reform to Support Higher Quality, More Affordable Cancer Care (PCOP)
Patient-Centered Oncology Payment: Payment Reform to Support Higher Quality, More Affordable Cancer Care (PCOP) May 2015 Summary Overview The American Society of Clinical Oncology (ASCO) has devoted considerable
More informationLegislative & Regulatory Update Brad Young, RxPlus Government Affairs
Legislative & Regulatory Update 2018 Brad Young, RxPlus Government Affairs Disclosures Brad Young reports no actual or potential conflicts of interest associated with this presentation. 2 Learning Objectives
More informationStatement Of. The National Association of Chain Drug Stores. For. U.S. Senate Committee on Finance. Hearing on:
Statement Of The National Association of Chain Drug Stores For U.S. Senate Committee on Finance Hearing on: 10:00 a.m. National Association of Chain Drug Stores (NACDS) 1776 Wilson Blvd., Suite 200 Arlington,
More informationUS H.R.6 of the 115 th Congress of the United States Session
US H.R.6 of the 115 th Congress of the United States 2017-2018 Session This Act may be cited as the Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities
More informationliterature that drug combinations containing butalbital should not be used in treatment of chronic pain and are not appropriate for long term routine
ACTION: Original BIA p(111397) pa(192459) d: (446870) DATE: 09/16/2013 2:14 PM print date: 04/02/2019 9:58 PM 1. Limit reimbursement for sedative hypnotic agents to the following medications: zolpidem
More informationPREPARED BY THE CENTER FOR MEDICARE ADVOCACY, INC.
MEDICARE DRUG CARDS PROVE INCONSISTENT AND PROVIDE FEW DISCOUNTS FOR MEDICARE BENEFICIARIES TRYING TO REDUCE THE COST OF THE TEN MOST POPULAR BRAND-NAME DRUGS USED BY SENIORS PREPARED BY THE CENTER FOR
More information2016 Drug Trends Series
Drug Trends Series Part 3: Assessing opioids and compounds Published August 2017 1 Drug Trends Series Opioids & Compounds First Script Introduction As with the first two editions in Coventry s Drug Trends
More informationPharmaceutical Management Medicaid 2019
Pharmaceutical Management Medicaid 2019 Toll-free Contact Number: (888) 327-0671 Pharmacy Administration: (810) 244-1660 Introduction Pharmaceutical Management promotes the use of the most clinically appropriate,
More informationThe Oregon Opioid Initiative. State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division
The Oregon Opioid Initiative State Pain & Opioid Conference Prescription Drug Monitoring May 2018 Lisa Millet, Public Health Division Disclosure No disclosures 2 Learning Objectives Learner will be able
More informationA LOOK AT ABUSE-DETERRENT OPIOIDS
JULY 2017 Drugs Under Review ICER s report reviewed evidence on ten abuse-deterrent formulations (ADF) of opioids. Nine of the drugs were extended release (ER) opioids, and one was immediate release (IR).
More informationBehavioral Health Hospital and Emergency Department Health Services Utilization
Behavioral Health Hospital and Emergency Department Health Services Utilization Rhode Island Fee-For-Service Medicaid Recipients Calendar Year 2000 Prepared for: Prepared by: Medicaid Research and Evaluation
More informationNews & Views. Antipsychotics on Maryland Medicaid PDL and Coverage of a 30-day Emergency Supply of Atypical Antipsychotics
Maryland Medicaid Pharmacy Program News & Views February 2011 Maryland Department of Health and Mental Hygiene /Office of Systems, Operations and Pharmacy Antipsychotics on Maryland Medicaid PDL and Coverage
More informationReducing Tobacco Use and Secondhand Smoke Exposure: Interventions to Increase the Unit Price for Tobacco Products
Reducing Tobacco Use and Secondhand Smoke Exposure: Interventions to Increase the Unit Price for Tobacco Products Task Force Finding and Rationale Statement Table of Contents Intervention Definition...
More informationMARYLAND BOARD OF PHARMACY
MARYLAND BOARD OF PHARMACY CONTRACEPTION REGULATIONSAnd Other Legislative Initiatives THE ROAD FROM CONCEPTUALIZATION TO IMPLEMENTATION Deena Speights-Napata Executive Director Maryland Board of Pharmacy
More informationBackground. Historical Context
Background In order to use prescription medications safely, consumers need to receive clear, actionable information. This medication information must be accurate, balanced, and delivered in a consistent
More informationLow Back Pain Report October 2013: Cost and Utilization of Health Care in Oregon
Low Back Pain Report October 2013: Cost and Utilization of Health Care in Oregon INTRODUCTION Most people in the United States will experience low back pain at least once during their lives. According
More informationStatement Of. The National Association of Chain Drug Stores. For. U.S. House of Representatives Committee on the Budget.
Statement Of The National Association of Chain Drug Stores For U.S. House of Representatives Committee on the Budget Hearing on: 2:00 p.m. 210 Cannon House Office Building National Association of Chain
More informationOpioid Prescribing Improvement Program
Opioid Prescribing Improvement Program Jeff Schiff, MD, MBA, Medical Director of Minnesota Health Care Programs Sarah Rinn, MPH, Opioid Prescribing Improvement Program Coordinator Agenda Opioid Prescribing
More informationDear Member: We look forward to serving you. Sincerely, Express Scripts
Dear Member: Welcome to Express Scripts, the company Eastern Kentucky University has chosen to manage your prescription drug plan. As one of the nation s leading prescription benefit managers, Express
More informationSafe, effective, affordable drug choices: online tool for payers and patients.
Executive summary: Rising healthcare costs and greater access to medical information drive patients to seek options for their drug therapy. The MedAlternatives database by Gold Standard/Elsevier empowers
More informationCosting report: Lipid modification Implementing the NICE guideline on lipid modification (CG181)
Putting NICE guidance into practice Costing report: Lipid modification Implementing the NICE guideline on lipid modification (CG181) Published: July 2014 This costing report accompanies Lipid modification:
More informationPrescription drug expenditures are the most rapidly growing component
Changing Prescribing Patterns and Increasing Prescription Expenditures in Medicaid Kenneth S. Fink, MD, MGA, MPH 1 Patricia J. Byrns, MD 2 1 Department of Family Medicine, University of North Carolina
More informationOHIO LEGISLATIVE SERVICE COMMISSION
OHIO LEGISLATIVE SERVICE COMMISSION Joseph Rogers and other LSC staff Fiscal Note & Local Impact Statement Bill: H.B. 117 of the 132nd G.A. Sponsor: Reps. Huffman and Brenner Status: As Introduced Local
More informationFigure 1: Quantity Dispensed/100 Members (Ambien and Sonata on left axis)
Sedative Hypnotic Quantity Limit Policy Impact Analysis Effective 12/6/2 OMAP implemented a 15 tablet per 3 day quantity limit on non-barbiturate sedative hypnotics for FFS patients. This policy was made
More informationEstimate of the Net Cost of A Prior Authorization Requirement for Certain Mental Health Medications. Prepared by. Driscoll & Fleeter.
Estimate of the Net Cost of A Prior Authorization Requirement for Certain Mental Health Medications Prepared by Driscoll & Fleeter for NAMI Ohio The National Alliance on Mental Illness Revised August 2008
More informationRestrictions to HCV Treatment in State Medicaid Programs
Center for Health Law and Policy Innovation of Harvard Law School Restrictions to HCV Treatment in State Medicaid Programs Acknowledgements: We are in the midst of merging/comparing data with other analysts
More informationAppendix C CHANGING THE TRAJECTORY:
Appendix C CHANGING THE TRAJECTORY: Impact of a Hypothetical Treatment That Slows the Progression of Alzheimer s In addition to the delayed onset scenario discussed in the report, another potential scenario
More informationPart D PDE Data and the Opioid Epidemic
Part D PDE Data and the Opioid Epidemic State Data Resource Center Acumen, LLC August 30, 2017 3:30-4:30pm ET Outline Background Information on Opioid Use Helpful Part D Elements for Analysis How to Perform
More informationE-Prescribing, EPCS & PDMP: An Update
E-Prescribing, EPCS & PDMP: An Update Melissa A. Kotrys, MPH Chief Executive Officer July 27, 2018 Arizona Health-e Connection is now Health Current Arizona s primary resource for health information technology
More informationHealth Care Reform Update and Advocacy Priorities
Health Care Reform Update and Advocacy Priorities Robert Greenwald Clinical Professor of Law Director, Center for Health Law and Policy Innovation of Harvard Law School October 2012 PRESENTATION OUTLINE
More informationThe Society welcomes the opportunity to respond the Department of Health s consultation on generic substitution.
Lindsey Gilpin Chairman of the English Pharmacy Board Telephone: 020 7572 2519 Fax: 0207 572 2501 e-mail: howard.duff@rpsgb.org 25 th March 2010 Dear Sir/Madam, Consultation on the proposals to implement
More informationGuide to Interchangeable Medicines
Guide to Interchangeable Medicines AUT-G0115-6 01 JUNE 2018 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only. CONTENTS 1 BACKGROUND 3 1.1
More informationOpioid Use and Misuse: History, Trends, And The Oregon Opioid Initiative
Opioid Use and Misuse: History, Trends, And The Oregon Opioid Initiative John W. McIlveen, Ph.D., LMHC, State Opioid Treatment Authority, Oregon Health Authority, Addictions and Mental Health Division
More informationPrescription Switching and Reduced LDL-C Goal Attainment
Prescription Switching and Reduced LDL-C Goal Attainment JoAnne M. Foody, MD, FACC, FAHA Brigham and Women's Hospital, Boston, MA Disclosures Consultant for Merck and Pfizer Why Address Adherence? Increasing
More information2016 Dr. Douglas H. Kay CPE Symposium
GREGORY CAMERON, R.Ph ASSISTANT PROFESSOR OF PHARMACY PRACTICE FIELD COORDINATOR COMMUNITY SITES HUSSON UNIVERSITY SCHOOL OF PHARMACY November 5, 2016 Please Silence All Electronic Equipment OBJECTIVES
More informationCalifornia Health Benefits Review Program. Analysis of California Assembly Bill 1601 Hearing Aids: Minors
California Health Benefits Review Program Analysis of California Assembly Bill 1601 Hearing Aids: Minors A Report to the 2017 2018 California State Legislature April 7, 2017 KEY FIN DINGS Key Findings:
More informationEXECUTIVE SUMMARY ENSURING PATIENT ACCESS TO SAFE, EFFECTIVE AND AFFORDABLE PRESCRIPTION MEDICINES // 2
EXECUTIVE SUMMARY Prescription drugs play a critical role in helping to prevent, manage and cure various conditions and diseases. Today, ground-breaking medicines are profoundly improving the conditions
More informationExplanatory Memorandum to accompany the following subordinate legislation-
Explanatory Memorandum to accompany the following subordinate legislation- 1. Care Standards Act 2000 (Extension of the Application of Part 2 to Private Dental Practices) (Wales) Regulations 2017, 2. Private
More informationDepartment of Legislative Services Maryland General Assembly 2010 Session
Department of Legislative Services Maryland General Assembly 2010 Session SB 27 Senate Bill 27 Finance FISCAL AND POLICY NOTE Revised (Senator Conway) Health and Government Operations Health Insurance
More informationImpact of Eliminating Medicaid Adult Dental Coverage in California on Emergency. Department Use for Dental Problems
Impact of Eliminating Medicaid Adult Dental Coverage in California on Emergency Department Use for Dental Problems Introduction: Oral health is an integral part of overall well-being. Apart from having
More informationPrescription Drugs North Carolina Policies. Carol Steckel, MPH Medicaid Director
Prescription Drugs North Carolina Policies Carol Steckel, MPH Medicaid Director March 19, 2013 Pharmacy Services Optional service provided each year to about 1.5 million beneficiaries by 2,200 pharmacy
More informationHOSPICE INFORMATION FOR MEDICARE PART D PLANS
HOSPICE INFORMATION FOR MEDICARE PART D PLANS SECTION I -HOSPICE INFORMATION TO OVERRIDE AN HOSPICE A3 REJECT OR TO UPDATE HOSPICE STATUS A. Purpose of the form (please check all appropriate boxes) : Admission
More informationSpecialty Drugs in Workers Compensation
Specialty Drugs in Workers Compensation A GUIDE FOR CLAIMS HANDLERS Specialty Drugs Specialty drugs have been developed in response to demand for specialized medications for complex medical conditions.
More informationLong-acting OPIOID Analgesics for Non-cancer Pain
Oregon Health Resources Commission Long-acting OPIOID Analgesics for Non-cancer Pain Subcommittee Report Update #1, July, 2003 This report is an update of the initial Opioid Subcommittee Report of June
More information2016 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan
2016 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan Plan Details, Programs, and Policies Table of Contents Click on the links below to be taken to that
More informationAll Indiana Medicaid Prescribers and Pharmacy Providers
P R O V I D E R B U L L E T I N BT200148 NOVEMBER 28, 2001 To: All Indiana Medicaid Prescribers and Pharmacy Providers Subject: Note: The information in this bulletin regarding prior authorization payment
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 6: Medicare Expenditures for Persons With CKD Medicare spending for patients with CKD aged 65 and older exceeded $50 billion in 2013, representing 20% of all
More informationWORKERS COMPENSATION AND PRESCRIPTION DRUGS: 2016 Update
September 2016 By Barry Lipton and David Colón WORKERS COMPENSATION AND PRESCRIPTION DRUGS: 2016 Update INTRODUCTION Prescription drug (Rx) costs represent a significant portion of workers compensation
More informationA Bill Regular Session, 2015 SENATE BILL 717
Stricken language would be deleted from and underlined language would be added to present law. 0 State of Arkansas 0th General Assembly As Engrossed: S// H// A Bill Regular Session, SENATE BILL By: Senator
More informationStrategies for Federal Agencies
Confronting Pain Management and the Opioid Epidemic Strategies for Federal Agencies Over the past 25 years, the United States has experienced a dramatic increase in deaths from opioid overdose, opioid
More informationPolicy Evaluation: Step Therapy Prior Authorization of Combination Inhaled Corticosteroid / Long-Acting Beta-Agonists
Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Policy Evaluation: Step Therapy Prior
More informationCost of Mental Health Care
Section 4 Cost of Mental Health Care Per capita mental health spending for Americans with a mental health diagnosis has increased among children, peaking in. For adults, the spending has been more stable.
More informationRisk Evaluation And Mitigation Strategies:
Risk Evaluation And Mitigation Strategies: The Experts Answer Questions from Health-System Pharmacists A midday symposium about the risk evaluation and mitigation strategies (REMS) required by the Food
More informationHow Mail-Servi. Prepared for
How Mail-Servi ice Pharmacies Will Save $46.6 Billion Over the Next Decade and the Cost of Proposed Restrictions Prepared for February 2012 Table of Contents I. Executive Summary... 3 Major Findings on
More informationTips for Evolving Medicaid Pharmacy Benefits Management (PBM) Programs. June 5, 2015
Tips for Evolving Medicaid Pharmacy Benefits Management (PBM) Programs 1 June 5, 2015 Introductions Mark Steck Pharm.D Independent Consultant, MAXIMUS John J.P. Crouse Vice President, MAXIMUS Market Lead
More informationTHE GENERAL ASSEMBLY OF PENNSYLVANIA SENATE BILL INTRODUCED BY DINNIMAN, FONTANA, SCHWANK, GREENLEAF, WARD AND FARNESE, APRIL 6, 2017
PRIOR PRINTER'S NO. 0 PRINTER'S NO. THE GENERAL ASSEMBLY OF PENNSYLVANIA SENATE BILL No. Session of 0 INTRODUCED BY DINNIMAN, FONTANA, SCHWANK, GREENLEAF, WARD AND FARNESE, APRIL, 0 SENATOR BAKER, HEALTH
More information2125 Rayburn House Office Building 2125 Rayburn House Office Building Washington, DC Washington, DC 20515
The Honorable Greg Walden Chairman Ranking Member 2125 Rayburn House Office Building 2125 Rayburn House Office Building Washington, DC 20515 Washington, DC 20515 Chairman Ranking Member Subcommittee on
More informationAn economic evaluation of rizatriptan in the treatment of migraine Thompson M, Gawel M, Desjardins B, Ferko N, Grima D
An economic evaluation of rizatriptan in the treatment of migraine Thompson M, Gawel M, Desjardins B, Ferko N, Grima D Record Status This is a critical abstract of an economic evaluation that meets the
More informationMay 16, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org May 16, 2014 Division of Dockets Management (HFA-305) Food and Drug Administration
More informationCost-Motivated Treatment Changes in Commercial Claims:
Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non- Medical Switching August 2017 THE MORAN COMPANY 1 Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non-Medical
More informationHuangdao People's Hospital
Table of contents 1. Background... 3 2. Integrated care pathway implementation... 6 (1) Workload indicators... 6 A. In eligible for care pathway... 6 B. Care pathway implementation... 7 (2) Outcome indicators...
More informationAmy Larrick Chavez-Valdez, Director, Medicare Drug Benefit and C & D Data Group
DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244-1850 CENTER FOR MEDICARE TO: FROM: SUBJECT: All Part D Sponsors Amy Larrick
More informationChapter 6: Healthcare Expenditures for Persons with CKD
Chapter 6: Healthcare Expenditures for Persons with CKD In this 2017 Annual Data Report (ADR), we introduce information from the Optum Clinformatics DataMart for persons with Medicare Advantage and commercial
More informationAgency Report Item 11: Oregon Health Authority Meningitis Vaccination Program in Lane County
Agency Report Item 11: Oregon Health Authority Meningitis Vaccination Program in Lane County Analyst: Linda Ames Request: Acknowledge receipt of a report on the meningitis vaccination program in Lane County.
More informationSub. S.B. 119 As Passed by the Senate
AM3404 Sub. S.B. 119 As Passed by the Senate Topic: Opioid Data and Communication Expansion Act moved to amend as follows: In line 1 of the title, after "4723.52," insert "4729.01, 4729.44, 4729.75, 4729.79,
More informationHUSKY Health Benefits and Prior Authorization Requirements Grid* Behavioral Health Partnership Effective: January 1, 2012
Behavioral Health Health and Behavior Assessments (CPT 96150-96155) When Performed by Psychologists Mental Health Inpatient 100% covered under medical benefit for members with diagnoses outside the range
More informationReport. Uganda Pharmaceutical Sector Scan JUNE 2010
Report On the Uganda Pharmaceutical Sector Scan Part of Component 1 of MeTA Baseline Assessments JUNE 2010 Drafted by consultants: 1. Samuel Balyejjusa, B.Pharm., MPH 2. Paschal Mujasi, B.Pharm., MBA 3.
More information1) Louisiana s Opioid Addiction 2) Adopting a Drug Formulary - HB 592 3) What is the ODG Drug Formulary and How is it Used in Workers Comp 4) The
1) Louisiana s Opioid Addiction 2) Adopting a Drug Formulary - HB 592 3) What is the ODG Drug Formulary and How is it Used in Workers Comp 4) The Role of Diagnosis (how it will work with the current treatment
More informationMail Order Is Not For Everyone!
Mail Order Is Not For Everyone! Face to face patient counseling by pharmacists can have a powerful impact on long term health care costs and quality. So, the way health plan sponsors promote mail and generics
More informationEvidence from a Pharmacy Access Program TERESA B. GIBSON, PHD SENIOR DIRECTOR, HEALTH OUTCOMES OCTOBER 27, 2011
Evidence from a Pharmacy Access Program TERESA B. GIBSON, PHD SENIOR DIRECTOR, HEALTH OUTCOMES OCTOBER 27, 2011 OVERVIEW Gibson TB, Mahoney J, Ranghell K, Cherney BJ, McElwee N. Value-Based Insurance Plus
More information9/25/15. Pharmacy Quality Measures: Financial Support. Learning Objectives. Speaker Disclosure. Access to Preferred Networks and Clinical Performance
Pharmacy Quality Measures: Action Steps for Improvement Financial Support Financial support was provided for this activity through an unrestricted grant from Health Mart Systems, Inc. Christine Jacobson
More informationPosition Paper on Good & Services Tax (GST) on Medicines Why All Medicines Should Be Accorded GST Zero- Rate Treatment in Malaysia
Position Paper on Good & Services Tax (GST) on Medicines Why All Medicines Should Be Accorded GST Zero- Rate Treatment in Malaysia INTRODUCTION: Medicines are essential and critical goods for all Malaysian
More informationSPECIAL ISSUE. Physicians Prescribing Responses to a Restricted Formulary: The Impact of Medicaid Preferred Drug Lists in Illinois and Louisiana
Physicians Prescribing Responses to a Restricted Formulary: The Impact of Medicaid Preferred Drug Lists in Illinois and Louisiana Suchin Virabhak, PhD; and Judith A. Shinogle, PhD Objective: To determine
More informationValue of Hospice Benefit to Medicaid Programs
One Pennsylvania Plaza, 38 th Floor New York, NY 10119 Tel 212-279-7166 Fax 212-629-5657 www.milliman.com Value of Hospice Benefit May 2, 2003 Milliman USA, Inc. New York, NY Kate Fitch, RN, MEd, MA Bruce
More informationProposals regarding the Cholesterol Lowering Pharmaceuticals Atorvastatin and Ezetimibe
26 April 2010 Proposals regarding the Cholesterol Lowering Pharmaceuticals Atorvastatin and Ezetimibe PHARMAC is seeking feedback on the following proposals relating to the cholesterol lowering pharmaceuticals
More informationClinical and economic outcomes of an ambulatory urinary tract infection disease management program Armstrong E P
Clinical and economic outcomes of an ambulatory urinary tract infection disease management program Armstrong E P Record Status This is a critical abstract of an economic evaluation that meets the criteria
More informationJanuary 16, Dear Administrator Verma:
Ms. Seema Verma Administrator Centers for Medicare and Medicaid Services Department of Health and Human Services Attention: CMMI New Direction P.O. Box 8011 Baltimore, MD 21244-1850 Re: (CMS-4182-P) Medicare
More information